Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes.

Abdel-Motal UM, Wang S, Awad A, Lu S, Wigglesworth K, Galili U.

Vaccine. 2010 Feb 17;28(7):1758-65. doi: 10.1016/j.vaccine.2009.12.015.

2.
3.

Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice.

Roodbari F, Sabahi F, Sarbolouki MN, Barkhordari F, Adeli A, Jamedar A, Mahboudi F.

Iran J Immunol. 2012 Jun;9(2):86-97. doi: IJIv9i2A2.

PMID:
22735796
4.

Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.

Abdel-Motal UM, Guay HM, Wigglesworth K, Welsh RM, Galili U.

J Virol. 2007 Sep;81(17):9131-41.

5.

A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.

Rodríguez D, Rodríguez JR, Llorente M, Vázquez I, Lucas P, Esteban M, Martínez-A C, del Real G.

J Gen Virol. 1999 Jan;80 ( Pt 1):217-23.

PMID:
9934705
6.

Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model.

Azizi A, Ghorbani M, Kryworuchko M, Aucoin S, Diaz-Mitoma F.

Hum Vaccin. 2005 Jul-Aug;1(4):170-6.

PMID:
17012859
7.

HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model.

Mahdavi M, Ebtekar M, Azadmanesh K, Khorramkhorshid HR, Rahbarizadeh F, Yazdi MH, Zabihollahi R, Abolhassani M, Hassan ZM.

Acta Virol. 2010;54(2):131-6.

PMID:
20545443
8.

Endotoxin-minimized HIV-1 p24 fused to murine hsp70 activates dendritic cells, facilitates endocytosis and p24-specific Th1 response in mice.

Krupka M, Zachova K, Cahlikova R, Vrbkova J, Novak Z, Sebela M, Weigl E, Raska M.

Immunol Lett. 2015 Jul;166(1):36-44. doi: 10.1016/j.imlet.2015.05.010.

PMID:
26021827
9.

Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.

Manches O, Plumas J, Lui G, Chaperot L, Molens JP, Sotto JJ, Bensa JC, Galili U.

Haematologica. 2005 May;90(5):625-34.

10.

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, Steinman RM.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9. doi: 10.1073/pnas.1019547108.

11.
13.
15.

Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity.

Lamalle-Bernard D, Munier S, Compagnon C, Charles MH, Kalyanaraman VS, Delair T, Verrier B, Ataman-Onal Y.

J Control Release. 2006 Sep 28;115(1):57-67.

PMID:
16919350
16.

Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes.

Grene E, Mezule G, Borisova G, Pumpens P, Bentwich Z, Arnon R.

AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):41-51.

PMID:
8989426
17.
18.

[Immunogenicity of recombinant adeno-asscociated virus type 1 expressing HIV-1 gp120 gene in mice and Rhesus macaques].

Yu SQ, Feng X, Liu HM, Yang HR, Li HX, Zeng Y.

Bing Du Xue Bao. 2010 Mar;26(2):115-20. Chinese.

PMID:
20480640
19.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14.

20.

Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.

Velashjerdi Farahani S, Reza Aghasadeghi M, Memarnejadian A, Faezi S, Shahosseini Z, Mahdavi M.

Pathog Glob Health. 2016 Mar;110(2):39-47. doi: 10.1179/2047773215Y.0000000035.

Supplemental Content

Support Center